Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ritlecitinib in moderate alopecia areata
2026-526355-62-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in alopecia areata comparing Ritlecitinib with Placebo (2 arms). Primary endpoint: SALT 0 at Week 24. Planned start Oct 2026; status: authorised.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on 2026-526355-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526355-62-00.